In Segment A, members will acquire unique doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants might be enrolled at the recognized monotherapy dosign routine. In Segment B, members will get oral ruxolitinib and ABBV-744 will be presented as "insert-on" therapy. In Phase C, contributors https://abbv-744anditsimpactongen02356.theisblog.com/32142069/rumored-buzz-on-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers